Outcomes of screening for prostate cancer among men who use statins
JAMA — Vettenranta A, Murtola TJ, Raitanen J, et al. | January 24, 2022
According to findings, the benefits conferred by prostate-specific antigen (PSA)-based screening are not materially compromised by statin use. PSA–based prostate cancer screening was found to be linked with less overdiagnosis of low-risk cancer in statin users, with similar mortality outcomes as in nonusers.
In this post hoc subgroup analysis of a cohort of 78,606 men in the Finnish Randomized Study of Prostate Cancer Screening, researchers investigated if statin use was linked with outcomes of a randomized PSA-based prostate cancer screening intervention.
Participants received three invitations for PSA screening at 4-year intervals from 1996 to 2007 vs routine care.
In statin nonusers, there was increased prostate cancer incidence in relation to PSA screening (screening vs control, 11.2 vs 8.6 per 1,000 person-years); rate ratio [RR], 1.31), but no similar rise in incidence was seen in statin users (6.9 vs 5.9 per 1000 person-years; RR, 1.02).
In statin users, a lower incidence of low-risk (Gleason score 6) and localized tumors was observed, whereas detection of tumors with a Gleason score of 8 to 10 was similar.
Screening was linked with a lower incidence of metastatic tumors irrespective of statin use.